Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Food for Thought. THTX chart v Immo by Trial Phase

<< Previous

Bullboard Posts

Next >>

Post by Wino115on Aug 23, 2021 2:06pm

234 Views

Post# 33749202

Food for Thought. THTX chart v Immo by Trial Phase

Food for thought. If the cut/past picture doesn't appear, here's the link:
User image

5x Phase 1 through Phase 2, 4x Phase 2 to Approval. All in, 20x....Equates to $70 a share. Only $7bil mkt cap.
$21bil takeover value ($90) equates to $210 share price for THTX. Is SORT1+ worth more than Trodelvy?
Further, Trodelvy is for only one indication..3L or greater mTNBC. And it received a CRL because of some issues.
Cut the stock in half.

The preclinical was started in 2007 and Fast track was granted late 2014. They started Phase 1 in 2013.
Various safety issues arose as they perfected the drug. So it was not without some hair on it.